Literature DB >> 7591740

ACE inhibitors for prophylaxis of migraine headaches.

W I Bender1.   

Abstract

Seventeen patients with migraine headaches, occurring at least twice a month, were successfully treated with an ACE inhibitor for prophylaxis. Most were given enalapril, some used lisinopril. Duration of treatment ranged from 3 months to 3 years. Side effects were generally not noted. Cough occurred in four patients. The mechanism of action is unknown. The lack of side effects and the presence of clearly sustained benefit in this small group of migraineurs should prompt further study and use of this class of drugs for prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591740     DOI: 10.1111/j.1526-4610.1995.hed3508470.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  8 in total

Review 1.  Practical considerations for the treatment of elderly patients with migraine.

Authors:  Paola Sarchielli; Maria Luisa Mancini; Paolo Calabresi
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  Role of angiotensin modulation in primary headaches.

Authors:  Erling Tronvik; Lars Jacob Stovner
Journal:  Curr Pain Headache Rep       Date:  2014-05

3.  Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study.

Authors:  H Schrader; L J Stovner; G Helde; T Sand; G Bovim
Journal:  BMJ       Date:  2001-01-06

Review 4.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

5.  Renin angiotensin system: A novel target for migraine prophylaxis.

Authors:  Ruchika Nandha; Harpal Singh
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

6.  Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial.

Authors:  Seyed Ali Sonbolestan; Kiyan Heshmat; Shaghayegh Haghjooy Javanmard; Mohammad Saadatnia
Journal:  Int J Prev Med       Date:  2013-01

Review 7.  New drugs for migraine.

Authors:  Lars Jacob Stovner; Erling Tronvik; Knut Hagen
Journal:  J Headache Pain       Date:  2009-10-01       Impact factor: 7.277

8.  Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients.

Authors:  Erling Tronvik; Lars J Stovner; Gunnar Bovim; Linda R White; Amanda J Gladwin; Kathryn Owen; Harald Schrader
Journal:  BMC Neurol       Date:  2008-03-26       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.